|
|
Vaccine Detail
|
VCL-CB01 Vaccine |
| Vaccine Information |
- Vaccine Name: VCL-CB01 Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007054
- Type: DNA vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- UL83
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Adjuvant: CRL1005 vaccine adjuvant
- Preparation: The vaccine contained plasmids encoding cytomegalovirus glycoprotein B and phosphoprotein 65, each at 2·5 mg/mL (ie, 5 mg overall per mL), formulated with poloxamer CRL1005 and benzalkonium chloride in phosphate-buffered saline (Kharfan-Dabaja et al., 2012).
- Description: This is for Leukemia Cancer and Lymphoma Cancer (NCT00285259). A vaccine consisting of two plasmids encoding the human cytomegalovirus (CMV) tegument phosphoprotein 65 (pp65), a major internal matrix protein, and glycoprotein B (gB), an important CMV component responsible for attachment and entry into cells, with immunostimulatory properties. Vaccination with VCL-CB01 may stimulate the host immune system to mount cellular and humoral immune responses against CMV positive cells, resulting in cell lysis (Kharfan-Dabaja et al., 2012; NCIT_C61327).
|
| Host Response |
|
|
| References |
Kharfan-Dabaja et al., 2012: Kharfan-Dabaja MA, Boeckh M, Wilck MB, Langston AA, Chu AH, Wloch MK, Guterwill DF, Smith LR, Rolland AP, Kenney RT. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. Infectious diseases. 2012; 12(4); 290-299. [PubMed: 22237175].
NCIT_C61327: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61327]
NCT00285259: [https://clinicaltrials.gov/show/NCT00285259]
|
|
